{"prompt": "['Cara Therapeutics, Inc., CR845', 'IND 123140, SN 0072', 'Cara Therapeutics, Inc.', 'Confidential', 'Page 27 of 92', 'CR845-CLIN3103', '5.0', 'Objectives', 'Primary Objective', 'To evaluate the efficacy of IV CR845 at a dose of 0.5 mcg/kg compared to', 'placebo in reducing the intensity of itch in hemodialysis patients with', 'moderate-to-severe pruritus.', 'Secondary Objectives', 'To evaluate the efficacy of IV CR845 at a dose of 0.5 mcg/kg compared to', 'placebo in improving itch-related quality-of-life measures in hemodialysis', 'patients with moderate-to-severe pruritus.', 'To evaluate the safety of IV CR845 at a dose of 0.5 mcg/kg in hemodialysis', 'patients with moderate-to-severe pruritus.', '10 September 2019', 'Version 2.2']['Cara Therapeutics, Inc., CR845', 'IND 123140, SN 0072', 'Cara Therapeutics, Inc.', 'Confidential', 'Page 28 of 92', 'CR845-CLIN3103', '6.0', 'Investigational Plan', '6.1', 'Overall Study Design and Plan: Description', 'This is a multicenter, randomized, double-blind, placebo-controlled study to evaluate the', 'safety and efficacy of IV CR845 at a dose of 0.5 mcg/kg administered after each dialysis', 'session. The study includes a Double-blind Phase and an Open-label Extension Phase.', 'CR845 will be evaluated relative to placebo over a 12-week Double-blind Treatment', 'Period in hemodialysis patients with moderate-to-severe pruritus. At the end of the', 'Double-blind Treatment Period, patients who received at least 30 doses of study drug', 'during the 12-week Double-blind Treatment Period will be eligible to receive open-label', 'CR845 for an additional 52 weeks. A follow-up visit will be conducted 7-10 days after', 'the last study visit on treatment or after early termination.', '6.1.1', 'Double-blind Phase', 'The Double-blind Phase of the study will consist of a Screening Visit, a 7-day Run-in', 'Period, and a 12-week Double-blind Treatment Period. Informed consent will be', 'obtained prior to performing any study-specific procedures. The Screening Visit will', 'occur within 7 to 28 days prior to randomization in order to assess eligibility. The', 'Screening Visit can be conducted during the Run-in Period at the discretion of the', 'Investigator.', '6.1.1.1', 'Screening Visit', 'During the Screening Visit, patients will sign the Informed Consent, and will be', 'evaluated for eligibility by assessment of inclusion/exclusion criteria, medical history,', 'physical examination, prescription dry body weight, pre-dialysis 12-lead', 'electrocardiogram, pre-dialysis vital signs, pre-dialysis hematology and serum chemistry,', 'adverse events, and prior medications.', 'Serum pregnancy test for females of childbearing potential must be performed within 7', 'days prior to the first study dose.', 'During Screening and before the first visit of the Run-in Period, patients will be trained', 'on completion of the 24-hour Worst Itching Intensity NRS scale. Patients may also be', 'trained on other patient-reported outcome (PRO) worksheets during Screening (ie,', 'Skindex-10 scale, 5-D itch scale and PGIC).', '6.1.1.2', 'Run-in Period', 'Eligible patients will complete a 7-day Run-in Period during the week prior to', 'randomization to confirm eligibility, preferably starting on the first dialysis session of', 'that week (ie, Monday for patients on a Monday-Wednesday-Friday dialysis schedule or', 'Tuesday for patients on a Tuesday-Thursday-Saturday dialysis schedule). The purpose of', 'the Run-in Period will be to confirm that each patient has moderate-to-severe pruritus', '(ie, weekly average score 5), as measured by the 24-hour Worst Itching Intensity NRS,', '10 September 2019', 'Version 2.2']['Cara Therapeutics, Inc., CR845', 'IND 123140, SN 0072', 'Cara Therapeutics, Inc.', 'Confidential', 'Page 29 of 92', 'CR845-CLIN3103', 'and to establish a baseline itch intensity. These criteria for eligibility should not be', \"communicated to the patients. This period will also be used to record each patient's use\", 'of itch medications.', 'During the first visit of the Run-in Period, patients will start the reporting of their Worst', 'Itching Intensity NRS daily score. Patients may continue to be trained on PRO', 'worksheets during the Run-in Period.', 'For consistency, patients will be requested to complete the NRS worksheets (either at', 'home or in the dialysis unit, as required) at a similar time of day around the normal start', 'time of their dialysis.', 'A Structured Safety Evaluation will be performed during the Run-in Period (preferably', 'on Wednesday/Thursday). The Structured Safety Evaluation is performed by study staff', 'using a list of specific signs/symptoms (eg, mental status change, falls, gait disturbance).', '6.1.1.3', 'Double-blind Treatment Period', 'If patients continue to meet all inclusion and no exclusion criteria at the end of the 7-day', 'Run-in Period, they will be randomized into the Double-blind Treatment Period in a', '1:1 ratio to receive either IV CR845 0.5 mcg/kg or placebo. Patients will be stratified', 'according to their use or non-use of concomitant medications to treat their itch as well as', 'the presence or absence of specific medical conditions.', 'Day 1 of the Double-blind Treatment Period will be defined as the day of administration', 'of the first dose of study drug and will occur preferably on the first dialysis day of the', 'first treatment week (ie, Monday for patients on a Monday-Wednesday-Friday dialysis', 'schedule or Tuesday for patients on a Tuesday-Thursday-Saturday dialysis schedule).', 'Patients will be administered CR845 or matched placebo as an IV bolus after the end of', 'each dialysis session during the 12-week Double-blind Treatment Period so that each', 'patient will receive CR845 or placebo 3 times weekly for a total of up to 36 doses.', 'During the Double-blind Treatment Period, patients will continue to report their Worst', 'Itching Intensity NRS score on a daily basis, covering the previous 24 hours. In addition,', 'during selected study visits (Day 1 and first day of Weeks 5, 9, 11, and 13 [ie, Days 29,', '57, 71, and 85]), they will complete other PRO measures (such as Skindex-10 Scale, 5-D', 'Itch Scale, and Patient Global Impression of Change). Patients will be instructed to', 'record patient-reported outcome measurements, including Worst Itching Intensity NRS', 'scores, at a similar time of day, whether in the dialysis unit (on dialysis days) or at home', '(on non-dialysis days).', 'Blood samples for inflammatory biomarkers will be collected for all randomized patients', 'prior to dialysis on Day 1 and prior to the last dialysis at the End-of-Treatment Visit for', 'the Double-blind Treatment Period (Day 85).', 'Clinical laboratory tests and vital signs will be monitored periodically, and adverse', 'events and concomitant medications will be continuously recorded during the Double-', '10 September 2019', 'Version 2.2']\n\n###\n\n", "completion": "END"}